Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. To date, there have been 32 approvals and 21 launches in the U.S. biosimilar market. As this market matures, its pipeline continues to grow.

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.